Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
Surpassing 1,000 Company Owned Company Operated stores
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
Subscribe To Our Newsletter & Stay Updated
